In major news released today, Cynata announced that it has entered into a License Option agreement with apceth GmbH & Co. KG. The agreement provides apceth with an option to certain uses of Cynata’s unique Cymerus™ mesenchymal stem cell (MSC) technology, exercisable by apceth into a definitive license agreement.
The relationship combines Cynata’s Cymerus MSC technology with apceth’s technologies for genetically modifying MSCs to open up prospective new therapeutic fields, particularly the treatment of cancer. This substantially broadens the commercial horizons for Cymerus, as it provides both an immediate cash payment as well as the potential to provide substantial license revenue in the form of milestones and royalties on eventual product sales. Cynata will work with apceth in the coming months to plan out the development path for the scope of the agreement and also explore other areas into which the relationship could be extended. [Read more…]